louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04791605: Gait Pattern Between a Cemented and Non-cemented Femur Stem
Official title: No Difference in Gait Pattern Between a Cemented and Non-cemented Femur Stem. 45 Prospective Randomized Total Hip Arthroplasty Patients After Acute Cervical Femur Fracture Evaluated After 2 Years
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Gait Analysis
Hip Fractures
Hip Arthroplasty
Randomized
Lead sponsor: Göteborg University
Sponsor class: OTHER
First posted: 2021-03-10
Enrollment: 45
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Gait of cemented femur stem of acute cervical collum femoris stem. Gait of non-cemented femur stem of acute cervical collum femoris stem.
Primary purpose: TREATMENT

Brief summary: Acute cervical femoral neck fracture patients randomized to either cemented or non-cemented stem. The investigators used gait analysis to evaluate if patients operated with a cemented stem showed more favourable hip kinematics and kinetics when compared with a group of patients operated with a non-cemented stem.

Detailed description: 45 patients randomized to receive either a cemented or a non-cemented stem were studied . 2 years after the operation gait analysis was performed with a 16-camera motion capture system together with 2 force-plates. Hip kinematics and kinetics were analysed and 70 subjects served as controls.

Eligibility criteria: Inclusion Criteria:

* acute collum femoris fracture

Exclusion Criteria:

-

Primary outcomes:
measure: Gait Analysis with focus on hip kinematics 2 year after total hip arthroplasty
timeFrame: 2 year postop
measure: Gait Analysis with focus on hip kinetics 2 year after total hip arthroplasty
timeFrame: 2 year postop
Secondary outcomes:
Other outcomes:
Locations:
city: Gothenburg
country: Sweden
facility: Roland Zügner
Study officials:
affiliation: Göteborg University
name: Roland Zügner
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00655005: Investigation of Pain and Symptom Burden in Patients With Newly Diagnosed Head and Neck Cancer
Official title: Investigation of Pain and Symptom Burden in Patients With Newly Diagnosed Head and Neck Cancer
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Head and Neck Cancer
Keywords: head and neck cancer
Lead sponsor: Vanderbilt-Ingram Cancer Center
Sponsor class: OTHER
Collaborators: name: National Cancer Institute (NCI)
First posted: 2008-04-09
Enrollment: 100
Sex: ALL
Minimum age (years): 21
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Newly diagnosed HNC patients.

Brief summary: RATIONALE: Collecting information by questionnaire about the quality of life of patients with head and neck cancer may help doctors learn more about the disease.

PURPOSE: This clinical trial is testing a questionnaire for assessing pain control, head and neck symptoms, and general symptoms of illness, demographics, moods, alcohol and tobacco history, and quality of life related to cancer in patients with newly diagnosed head and neck cancer.

Detailed description: OBJECTIVES:

* To pilot test a questionnaire measuring the collection of the following data from patients with newly diagnosed head and neck cancer: head and neck cancer-related symptoms, general demographics, pain control, general symptoms, mood, smoking and drinking history, and quality of life.
* To identify questions that may be unclear or difficult for patients to understand.
* To determine the time required for each patient to complete the questionnaire and assess the feasibility and burden to the patient.
* To determine the baseline incidence of symptoms and psychosocial issues in these patients.

OUTLINE: Patients complete a timed questionnaire comprising questions of head and neck symptoms, demographic information, pain control, symptom control, mood, smoking and drinking history, and anxiety and depression under the supervision of the investigator.

Eligibility criteria: Inclusion Criteria:

* Diagnosis of head or neck carcinoma

  * Newly diagnosed disease
* Able to speak English
* Able to give informed consent

Exclusion Criteria:

Not specified

PRIOR CONCURRENT THERAPY:

* Not specified

Primary outcomes:
measure: Pilot questionnaire testing of related symptoms, general demographics, pain control, general symptoms, mood, smoking and drinking history, and quality of life
timeFrame: at time of patient exam
Secondary outcomes:
measure: Time required for questionnaire completion by each patient
timeFrame: at time of patient exam
measure: Feasibility and patient burden assessment
timeFrame: at time of patient exam
measure: Baseline incidence of symptoms and psychosocial issues
timeFrame: at time of patient exam
Other outcomes:
Locations:
city: Nashville
country: United States
facility: Vanderbilt-Ingram Cancer Center
state: Tennessee
Study officials:
affiliation: Vanderbilt-Ingram Cancer Center
name: Barbara Murphy, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01472705: Everolimus- Versus Biolimus-Eluting Stents in All-Comers
Official title: Long-Term Comparison of Everolimus-Eluting and Biolimus-Eluting Stents in All-Comer Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Coronary Artery Disease
Keywords: drug-eluting coronary stent
percutaneous coronary intervention
Lead sponsor: University of Freiburg
Sponsor class: OTHER
First posted: 2011-11-16
Enrollment: 814
Sex: ALL
Minimum age (years): 18
Maximum age (years): 120
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: All consecutive patients treated at our institution with at least one BES or EES

Brief summary: This study sought to investigate safety and efficacy of biolimus-eluting stents (BES) with biodegradable polymer as compared with everolimus-eluting stents (EES) with durable polymer through 3 years of follow-up.

Detailed description: A group of 814 consecutive patients undergoing percutaneous coronary intervention (PCI) was enrolled between 2007 and 2010, of which 527 were treated with EES and 287 with BES implantation. Clinical outcome was compared in 200 pairs using propensity score matching. The primary endpoint was a composite of death, myocardial infarction (MI) and target vessel revascularisation (TVR) at two-year follow-up.

Eligibility criteria: Inclusion Criteria:

* all patients with at least one BES or EES for de novo stenosis

Exclusion Criteria:

* patients with at least one non-study stent
* patients with both study stent
* patients with life expectancy \< 3 years

Primary outcomes:
measure: Composite of Death, Myocardial Infarction and Target Vessel Revascularization
timeFrame: up to 24 months
Secondary outcomes:
measure: Cardiovascular death
timeFrame: up to 24 months
measure: Any Revascularization
timeFrame: up to 24 months
Other outcomes:
Locations:
city: Fribourg
country: Switzerland
facility: Cardiology, university Fribourg Medical Center
Study officials:
affiliation: University Fribourg
name: Stéphane P Cook, MD
role: STUDY_CHAIR
affiliation: University Fribourg
name: Mario Togni, MD
role: STUDY_DIRECTOR
affiliation: University Fribourg
name: Markus Oberhänsli, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Puricel S, Oberhansli M, Guntern P, Lehmann S, Goy JJ, Arroyo D, Villeneuve H, Baeriswyl G, Stauffer JC, Togni M, Cook S. Long-term comparison of everolimus-eluting and biolimus-eluting stents. EuroIntervention. 2013 Jul;9(3):336-44. doi: 10.4244/EIJV9I3A55.
citation: Arroyo D, Togni M, Puricel S, Gerard B, Sonja L, Corpataux N, Villeneuve H, Boute E, Stauffer JC, Goy JJ, Cook S. Comparison of everolimus-eluting and biolimus-eluting coronary stents with everolimus-eluting bioresorbable scaffold: study protocol of the randomized controlled EVERBIO II trial. Trials. 2014 Jan 7;15:9. doi: 10.1186/1745-6215-15-9.
Clinical trial NCT00440505: Effect of Nicotine on Chronic Pelvic Pain
Official title: Effect of Nicotine on Chronic Pelvic Pain
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Pelvic Pain
Keywords: chronic pain
pelvic pain
nicotine patch
Lead sponsor: Columbia University
Sponsor class: OTHER
First posted: 2007-02-27
Enrollment: 20
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to test whether transdermal nicotine reduces pain among women with chronic pelvic pain.

Detailed description: Potential subjects are female non-smokers presenting to their physicians for treatment of chronic pelvic pain. When consented, the subjects fill out a questionnaire on demographic information and pain experience. The trial is conducted at home over three days. Each subject uses three different levels of nicotine (0mg, 5mg, and 10mg) administered in a random order; the study is double-blinded and patients act as their own controls. Subjects apply the placebo or nicotine patches in the morning and remove them in the evening when they fill out a pain diary for the day. During the study, patients will continue their typical course of pain medication and report pain medication use in the pain diary.

Eligibility criteria: Inclusion Criteria:

* Chronic pelvic pain
* Aged 18-60 years
* Female

Exclusion Criteria:

* Uncontrolled hypertension
* Cardiovascular disease
* Current analgesic abuse
* Pregnancy
* Current usage of nicotine patch or gum
* Allergy to adhesive tape

Primary outcomes:
measure: Pain Score
timeFrame: 1 day
Secondary outcomes:
measure: Patient Self-assessment of Psychological Distress
timeFrame: 1 day
measure: Number of Participants Who Reported an Increase in Daily Pain Medication Regime
timeFrame: 1 day
measure: Nausea
timeFrame: 1 day
Other outcomes:
Locations:
city: New York
country: United States
facility: Columbia University Medical Center
state: New York
Study officials:
affiliation: Columbia University
name: Pamela Flood, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Columbia University
name: Jessamyn Conell-Price, BA
role: STUDY_DIRECTOR
References:
Clinical trial NCT03291405: Correlation Between Body Mass Index and Gonadotrophin Secretions in Pcos Patients and Their Effect on Ivf Outcome
Official title: Correlation Between Body Mass Index and Gonadotrophin Secretions in Pcos Patients and Their Effect on Ivf Outcome (Randamized Control Trial)
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Correlation Between Body Mass Index and Gonadotrophin Secretions in Pcos Patients and Their Effect on Ivf Outcome
Lead sponsor: Ain Shams University
Sponsor class: OTHER
First posted: 2017-09-25
Enrollment: 142
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: total of 142 women will be involved

Brief summary: It is Correlation Between Body Mass Index and Gonadotrophin Secretions in Pcos Patients and Their Effect on Ivf Outcome


Eligibility criteria: Inclusion Criteria:

* cases of PCO

Exclusion Criteria:

* amenorrhea
* womenwho had previous IVF

Primary outcomes:
measure: Gonadotrophin Secretions in both groups
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Ain Shams University
Study officials:
References:
Clinical trial NCT05910905: Clinical Efficacy of Preformed Pediatric Zirconia and Metal Crown
Official title: Evaluation of Clinical Efficacy of Preformed Pediatric Zirconia Crown and Preformed Pediatric Metal Crown: A Randomized Clinical Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Carious Teeth
Lead sponsor: Marmara University
Sponsor class: OTHER
First posted: 2023-06-20
Enrollment: 50
Sex: ALL
Minimum age (years): 6
Maximum age (years): 9
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The study was planned to evaluate and compare the clinical success of prefabricated stainless steel crowns and zirconia crowns used in the primary molars.

The study will be carried out in healthy children aged 6-9 years with caries on more than one surface of the primary molars.

Detailed description: In this study, zirconia crowns will be compared with prefabricated stainless steel crowns in a randomized controlled manner. The study will be conducted in split-mouth to eliminate the effect of potential confounders. The obtained data will be analyzed using appropriate statistical methods.

Eligibility criteria: Inclusion Criteria:

* Healthy children aged 6-9 years with caries on primary molars
* Children without systemic disease or developmental dental anomalies that may affect caries susceptibility.
* Children whose cooperation is 'positive' or 'absolutely positive' according to the Frankl behavioral scale (Frankl et al., 1962).
* Those with deep dentin caries that do not extend to the pulp in the teeth to be treated
* The molars will be treated with a crown indication.
* Presence of symmetry of the primary molar to be treated in the opposite arch.
* The molar to be treated is in occlusion with the antagonist.
* Presence of caries on at least two surfaces of the molars to be treated.
* Absence of spontaneous pain, abscess, mobility, interradicular lesion in the tooth to be treated
* Patients whose parents and themselves agree to participate in the treatment

Exclusion Criteria:

* Children whose treatment cannot be continued on the dental chair due to cooperation
* Molars that will soon be exfoliated, 1/2 of the root has been resorbed
* The presence of bruxism
* The presence of erosion or attrition-related wear on the opposing molar
* The patient does not come to the control appointment or does not want to continue to the research
* Have allergy to local anesthetic, nickel or chromium
* Complications during treatment.

Primary outcomes:
measure: Comparison of clinical success
timeFrame: 24 month
Secondary outcomes:
measure: Parental satisfaction
timeFrame: 24 month
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03895905: Comparison of Cervical Pathologies in the Presence of High Risk Hpv Positivity
Official title: Comparison of Cervical Pathologies in the Presence of High Risk Hpv Positivity in Normal Women With Cytology
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Human Papilloma Virus
Cervical Neoplasm
Keywords: colposcopy
High Risk HPV
Lead sponsor: Kanuni Sultan Suleyman Training and Research Hospital
Sponsor class: OTHER
First posted: 2019-03-29
Enrollment: 409
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with high-risk HPV and colposcopy were the study groups.

Brief summary: The only malignancy screening test among gynecological cancers is cervical cancer.

Cytology examination and Hpv typing with smear are used as screening tests. Hpv positivity is detected in more than 90% of cervical cancers. However, only the Hpv 16-18 type positive patients undergo colposcopy in the routine screening program.

Patients with Smear negative, Type 16-18 high-risk Hpv positivity are evaluated by quota after 1 year.

the authors performed colposcopy with this study; authors aimed to compare the results of patients with type 16-18 Hpv positivity and type 16-18 high-risk Hpv positivity and to find out whether there was any difference between them.

In this way, other high-risk Hpv types other than type 16-18 (31,33,35,45,51, etc.) may be exposed to premalign cervical lesions and possible cancer in a number of earlier and earlier periods by performing colposcopic examination instead of expecting to perform quota after 1 year. we aimed to remove.


Eligibility criteria: Inclusion Criteria:

* 20-65 years old
* patients with normal smear

Exclusion Criteria:

* Patients with invasive cervical cancer,
* HIV-positive patients,
* ASCUS and more risky premalignant lesions in cytology,
* Over the age of 65 and
* Patients under 20 years of age,
* patients with another known gynecological malignancy

Primary outcomes:
measure: Genotype of HR-HPV 16/18
timeFrame: 1 MONTH
measure: Genotype of HR-HPV non 16/18
timeFrame: 1 MONTH
Secondary outcomes:
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Kanuni Sultan Süleyman Training and Research Hospital
Study officials:
References:
Clinical trial NCT04077905: Pegylated Liposomal Doxorubicin as a Induction Therapy for Lymphoma Induced Hemophagocytic Lymphohistiocytosis.
Official title: A Prospective Study on the Modified DEP Regimen Induction Therapy in Lymphoma Induced Hemophagocytic Lymphohistiocytosis
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Hemophagocytic Lymphohistiocytosis
Keywords: pegylated liposomal doxorubicin
Lead sponsor: Beijing Friendship Hospital
Sponsor class: OTHER
First posted: 2019-09-04
Enrollment: 160
Sex: ALL
Minimum age (years): 2
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study aimed to investigate the efficacy and safety of pegylated liposomal doxorubicin together with etoposide and methylprednisolone as a induction therapy for lymphoma induced hemophagocytic lymphohistiocytosis.


Eligibility criteria: Inclusion Criteria:

* 1.Diagnosed as lymphoma-Hemophagocytic Lymphohistiocytosis.
* 2.Patients were older than 2 years of age.
* 3.Estimated survival time ≥ 1 week.
* 4.Cardiac ultrasound LVEF≥50%; No Active bleeding of the internal organs(digestive tract, lung, brain, etc.); If the patient has dyspnea, oxygenation index \>250.
* 5.sign informed consent.

Exclusion Criteria:

* 1.Heart function above grade II (NYHA).
* 2.Accumulated dose of doxorubicin above 400mg/m2 、epirubicin above 750mg/m2、pirarubicin above 800mg/m2 or the patients treated with anthracycline induced cardiovascular disease.
* 3.Pregnancy or lactating Women.
* 4.Allergic to pegylated liposomal doxorubicin or etoposide.
* 5.Active bleeding of the internal organs.
* 6.HIV antibody positivity.
* 7.Acute or chronic active hepatitis B (HBsAg positivity, HBV DNA negative acceptable), acute or chronic active hepatitis C (HCV antibody negatively acceptable; HCV antibody positivity, HCV RNA negative acceptable).
* 8.Participate in other clinical research at the same time.
* 9.The researchers considered that patients are not suitable for the study.

Primary outcomes:
measure: Response rate
timeFrame: Time Frame: 1 years
Secondary outcomes:
measure: Response rate of lymphoma
timeFrame: Time Frame: 1 years
measure: Progression Free Survival
timeFrame: Time Frame: 1 years
measure: Overall Survival
timeFrame: Time Frame: 1 years
measure: Adverse Events
timeFrame: Time Frame: 1 years
Other outcomes:
Locations:
city: Beijing
country: China
facility: Beijing Friendship Hospital
Study officials:
References:
citation: Pi Y, Wang J, Zhou H, Ye X, Sun X, Liu L, Pan X, Wang Z. Modified DEP regimen as induction therapy for lymphoma-associated hemophagocytic lymphohistiocytosis: a prospective, multicenter study. J Cancer Res Clin Oncol. 2023 Jul;149(7):3033-3041. doi: 10.1007/s00432-022-04157-0. Epub 2022 Jul 19.
Clinical trial NCT01256905: Attention Modulation for Treatment of Parkinson's Disease and Dementia With Lewy Bodies
Official title: Attention Modulation for Treatment of Parkinson's Disease and Dementia With Lewy Bodies
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Parkinsons Disease
Lewy Bodies Disease
Lead sponsor: NYU Langone Health
Sponsor class: OTHER
Collaborators: name: Cephalon
First posted: 2010-12-09
Enrollment: 0
Sex: ALL
Minimum age (years): 50
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate if a drug commonly used to treat excessive day-time sleepiness, called armodafinil (Nuvigil), is also effective in improving the impairment in the attention commonly reported by patients with more advanced Parkinson's disease (PD) and Lewy body disease (LBD).

Detailed description: The main aims of this study are:

1. To investigate whether in PDD and DLB th specific disturbances in the basal ganglia thalamocortical network, measured through the Electroencephalography (EEG) frequency analysis, are ameliorated by armodafinil.

Our main hypothesis is that armodafinil can restore the attention and improve cognitive disturbances in PDD and DLB, through a specific effect on striatal-thalamo-cortical activity.

Eligibility criteria: Inclusion Criteria:

* Established criteria for diagnosis of PDD (Parkinsons Disease) {Emre M et al. Mov Disord 2007;22:1689-707} and DLB (Lewy Bodies Disease) {McKeith et al. Neurology 2005;65:1863-72}
* Mini Mental State Examination (MMSE) score between \<24; and/or Dementia Rating
* Scale-2 (DRS-2) score \<134;
* Clinical Assessment of Fluctuation (CAF)\>4;
* Stable anti-parkinsonian medication in the 4 weeks preceding the study

Exclusion Criteria:

* Use of cognitive enhancers (Donepezil, Rivastigmine, Galantamine, Modafinil, Memantine) in the last 4 weeks:

Concomitant use of any medication contraindicated with modafinil/armodafinil; History of alcohol and substances abuse. Use of medications known to alter the normal EEG activity in humans during the study period (i.e. clonazepam) History of psychiatric disorders, other than depression and psychiatric complication of PDD and DLB

Primary outcomes:
measure: EGI netstation software (Electrical Geodesics Inc.) and a custom made software that runs on the Matlab platform (The Mathworks)
timeFrame: 2 hours
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: NYU Parkinsons and Movement Disorders Center
state: New York
Study officials:
affiliation: NYU Parkinsons and Movement Disorders Center
name: Sara Varanese, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03838705: The Relationship Between Postoperative Oxygenation and STOP-BANG Questionnaire and 4-V Tool
Official title: The Relationship Between Postoperative Oxygenation and STOP-BANG Questionnaire and 4-V Tool in Preoperative Bariatric Surgery Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hypoxia
Bariatric Surgery
Keywords: stop-bang, bariatric surgery, obesity, hypoxia
Lead sponsor: Umraniye Education and Research Hospital
Sponsor class: OTHER_GOV
Collaborators: name: Sibel Ocak Serin
name: Aysun Isiklar
First posted: 2019-02-12
Enrollment: 87
Sex: ALL
Minimum age (years): 21
Maximum age (years): 64
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SCREENING

Brief summary: In our study, we aimed to investigate the relationship between STOP-BANG and 4-Variable Screening questionnaires in postoperative period in patients who underwent bariatric surgery.


Eligibility criteria: Inclusion Criteria:

* BMI\>40
* bariatric surgery patients

Exclusion Criteria:

* malignancy
* patients who are unable to complete the questionnaire
* patients who needs laparotomy

Primary outcomes:
measure: SpO2
timeFrame: 48 hours
Secondary outcomes:
measure: STOP-BANG
timeFrame: preoperative 24 hours
measure: 4-V Tool
timeFrame: preoperative 24 hours
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Istanbul Umraniye Training Hospital
Study officials:
affiliation: Umraniye Research Hospital
name: Sibel O Serin, MD
role: STUDY_DIRECTOR
References: